BioVie to Present at ThinkEquity Conference in NYC on May 2nd

Tailwinds' Take: this could mark the official coming out party for BioVie, which has never before presented at an investor conference (to the best...

BioVie, An Undiscovered Gem

People who are good at what they do consistently outperform. This is true of many things like sports, entertainment and business. People like Roger...

BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory...

LOS ANGELES, Feb. 06, 2019 (GLOBE NEWSWIRE) -- BioVie Inc. (OTCQB: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for...

BioVie’s New Drug Candidate BIV201 Receives FDA Orphan Drug Designation for the Treatment of...

LOS ANGELES, CA / ACCESSWIRE / November 28, 2018 / BioVie Inc. (OTCQB: BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.